SIGMA Pharmaceuticals agreed
to extend the exclusivity period
granted to suitor Aspen
Pharmacare regarding a possible
takeover of the company.
Late on Friday afternoon Sigma
said that the original agreement
gave the South African company
“limited exclusivity” for four weeks,
and now in response to a request
from Aspen Sigma has agreed to
extend the exclusivity period to 05
July “to enable Aspen to complete
its due diligence review”.
Sigma once again recommended
that shareholders take no action at
this time, saying “the due diligence
process being undertaken by Aspen
may or may not result in a formal
proposal or a recommendation by
the Board.”The above article was sent to subscribers in Pharmacy Daily's issue from 29 Jun 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Jun 10
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.